Darleukin
As of the edition of 20 October 2026, Darleukin is a protein: stopped in 2025; acts on FN1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Protein
- Registered trials
- 4, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FN1 | Fibronectin | P02751 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 0 | 0 | 3 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Philogen | Lead sponsor of trials | 2013 to now |